Rifabutin NDC 72319-010

NDC codes

FDA NDC Directory

Product NDC (as listed)72319-010Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72319-0010Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72319-010-04	72319001004	100 CAPSULE in 1 BOTTLE (72319-010-04)Marketed from Apr 16, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Rifabutin
Generic name (nonproprietary): rifabutin
Active ingredients: Rifabutin — 150 mg/1
Dosage form: Capsule
Route: Oral
Labeler: i3 Pharmaceuticals, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 212430
Marketing start: Apr 16, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Rifamycins (Chemical structure)
Identifiers: Product ID 72319-010_4efa116e-c5b0-d87e-e063-6394a90a5077SPL ID 4efa116e-c5b0-d87e-e063-6394a90a5077SPL set ID fd6062e2-17c8-48f4-a1fe-69ebe410f583RxCUI 198200UNII 1W306TDA6SUPC 0372319010040
Pharmacologic class: Rifamycin Antimycobacterial

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472319001004 followed by a unit qualifier and the quantity

Package 72319-0010-04. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 20, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Rifabutin capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 212430

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 212430
Product	Strength	Form · route	Labeler	Product NDC
Rifabutin	Rifabutin 150 mg/1	CapsuleOral	A2A Integrated Pharmaceuticals	73141-020